However, considering that IL-8 expression is increased in OC tissues and that the neutralizing IL-8 antibody HuMax-IL8 (BMS-986253) and the CXCR1/2 inhibitor SX-682 are well tolerated, future clinical studies should assess whether the combination of IL-8 and PD-1/PD-L1 blockade might increase the effectiveness of PD-1/PD-L1-targeting immunotherapies in ovarian cancer patients. Here, CXCL8 is linked to ovarian carcinoma.